{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T21:17:45Z","timestamp":1795036665396,"version":"4.10.2"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":1860,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.7861\/clinmedicine.19-2-169","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T16:25:24Z","timestamp":1552580724000},"page":"169-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":270,"title":["Neuromyelitis optica spectrum disorders"],"prefix":"10.1016","volume":"19","author":[{"given":"Saif","family":"Huda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Whittam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maneesh","family":"Bhojak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel","family":"Noonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kneen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.7861\/clinmedicine.19-2-169_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-2094-10-8","article-title":"The history of neuromyelitis optica","volume":"10","author":"Jarius","year":"2013","journal-title":"J Neuroinflammation"},{"key":"10.7861\/clinmedicine.19-2-169_bib2","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.7861\/clinmedicine.19-2-169_bib3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.7861\/clinmedicine.19-2-169_bib4","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"key":"10.7861\/clinmedicine.19-2-169_bib5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"10.7861\/clinmedicine.19-2-169_bib6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-med-043010-193843","article-title":"Aquaporins in clinical medicine","volume":"63","author":"Verkman","year":"2012","journal-title":"Ann Rev Med"},{"key":"10.7861\/clinmedicine.19-2-169_bib7","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/1352458515571446","article-title":"Role of membrane complement regulators in neuromyelitis optica","volume":"21","author":"Saadoun","year":"2015","journal-title":"Mult Scler"},{"key":"10.7861\/clinmedicine.19-2-169_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1212\/NXI.0000000000000311","article-title":"Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro","volume":"4","author":"Takeshita","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.7861\/clinmedicine.19-2-169_bib9","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology"},{"key":"10.7861\/clinmedicine.19-2-169_bib10","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20081241","article-title":"Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2","volume":"205","author":"Hinson","year":"2008","journal-title":"J Exp Med"},{"key":"10.7861\/clinmedicine.19-2-169_bib11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/nyas.12794","article-title":"Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later","volume":"1366","author":"Pittock","year":"2016","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.7861\/clinmedicine.19-2-169_bib12","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1212\/NXI.0000000000000468","article-title":"Mortality in neuromyelitis optica is strongly associated with African ancestry","volume":"5","author":"Mealy","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.7861\/clinmedicine.19-2-169_bib13","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica","volume":"21","author":"Pandit","year":"2015","journal-title":"Mult Scler J"},{"key":"10.7861\/clinmedicine.19-2-169_bib14","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1136\/jnnp-2017-317566","article-title":"Worldwide prevalence of neuromyelitis optica spectrum disorders","volume":"89","author":"Masahiro","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.7861\/clinmedicine.19-2-169_bib15","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/archneurol.2012.249","article-title":"Effects of age and sex on aquaporin-4 autoimmunity","volume":"69","author":"Quek","year":"2012","journal-title":"Arch Neurol"},{"key":"10.7861\/clinmedicine.19-2-169_bib16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1212\/NXI.0000000000000339","article-title":"Female hormonal exposures and neuromyelitis optica symptom onset in a multicentre study","volume":"4","author":"Bove","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.7861\/clinmedicine.19-2-169_bib17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1212\/WNL.0b013e3181ea9f15","article-title":"Familial neuromyelitis optica","volume":"75","author":"Matiello","year":"2010","journal-title":"Neurology"},{"key":"10.7861\/clinmedicine.19-2-169_bib18","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/s41467-018-04332-3","article-title":"A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica","volume":"9","author":"Estrada","year":"2018","journal-title":"Nature Communications"},{"key":"10.7861\/clinmedicine.19-2-169_bib19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non-organ specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol"},{"key":"10.7861\/clinmedicine.19-2-169_bib20","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1136\/jnnp.2004.055491","article-title":"Gluten sensitivity and neuromyelitis optica: two case reports","volume":"76","author":"Jacob","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.7861\/clinmedicine.19-2-169_bib21","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","article-title":"Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients","volume":"78","author":"Leite","year":"2012","journal-title":"Neurology"},{"key":"10.7861\/clinmedicine.19-2-169_bib22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.7861\/clinmedicine.19-2-169_bib23","first-page":"1","article-title":"Frequency of aquaporin-4 immunoglobulin G in longitudinally extensive transverse myelitis with antiphospholipid antibodies","volume":"10","author":"Guerra","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.7861\/clinmedicine.19-2-169_bib24","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.7861\/clinmedicine.19-2-169_bib25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1352458512457720","article-title":"Neuropathic pruritus (itch) in neuromyelitis optica","volume":"19","author":"Elsone","year":"2012","journal-title":"Mult Scler J"},{"key":"10.7861\/clinmedicine.19-2-169_bib26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/archneurol.2011.832","article-title":"Association Between Paroxysmal Tonic Spasms and Neuromyelitis Optica","volume":"69","author":"Usmani","year":"2012","journal-title":"Arch Neurol"},{"key":"10.7861\/clinmedicine.19-2-169_bib27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jamaneurol.2014.2137","article-title":"Short myelitis lesions in aquaporin-4-IgG\u2013positive neuromyelitis optica spectrum disorders","volume":"72","author":"Flanagan","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.7861\/clinmedicine.19-2-169_bib28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.brainresrev.2007.06.002","article-title":"The circumventricular organs: An atlas of comparative anatomy and vascularization","volume":"56","author":"Duvernoy","year":"2007","journal-title":"Brain Research Reviews"},{"key":"10.7861\/clinmedicine.19-2-169_bib29","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/1352458513507822","article-title":"Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients","volume":"20","author":"Kremer","year":"2013","journal-title":"Mult Scler J"},{"key":"10.7861\/clinmedicine.19-2-169_bib30","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/archneurol.2009.264","article-title":"Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications","volume":"66","author":"Kanbayashi","year":"2009","journal-title":"Arch Neurol"},{"key":"10.7861\/clinmedicine.19-2-169_bib31","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"key":"10.7861\/clinmedicine.19-2-169_bib32","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/jnnp-2016-314005","article-title":"Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease","volume":"88","author":"Jury\u00b4nczyk","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.7861\/clinmedicine.19-2-169_bib33","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/cen3.12107","article-title":"Evaluation of aquaporin-4 antibody assays","volume":"5","author":"Waters","year":"2014","journal-title":"Clin Exp Neuroimmunol"},{"key":"10.7861\/clinmedicine.19-2-169_bib34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/1352458516663853","article-title":"The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates","volume":"23","author":"Hamid","year":"2017","journal-title":"Mult Scler"},{"key":"10.7861\/clinmedicine.19-2-169_bib35","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1212\/WNL.0000000000002655","article-title":"Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder","volume":"86","author":"Hyun","year":"2016","journal-title":"Neurology"},{"key":"10.7861\/clinmedicine.19-2-169_bib36","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ana.20770","article-title":"Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis","volume":"59","author":"Weinshenker","year":"2006","journal-title":"Ann Neurol"},{"key":"10.7861\/clinmedicine.19-2-169_bib37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","article-title":"Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures","volume":"306","author":"Jarius","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.7861\/clinmedicine.19-2-169_bib38","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/1352458514567216","article-title":"Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography","volume":"21","author":"Bennett","year":"2015","journal-title":"Mult Scler"},{"key":"10.7861\/clinmedicine.19-2-169_bib39","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J Neurol"},{"key":"10.7861\/clinmedicine.19-2-169_bib40","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.7861\/clinmedicine.19-2-169_bib41","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jury\u00b4nczyk","year":"2017","journal-title":"Brain"},{"key":"10.7861\/clinmedicine.19-2-169_bib42","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult Scler J"},{"key":"10.7861\/clinmedicine.19-2-169_bib43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","article-title":"Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin-4 IgG disease","volume":"75","author":"Hamid","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.7861\/clinmedicine.19-2-169_bib44","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.7861\/clinmedicine.19-2-169_bib45","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1212\/WNL.0000000000005619","article-title":"Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder","volume":"90","author":"Hacohen","year":"2018","journal-title":"Neurology"},{"key":"10.7861\/clinmedicine.19-2-169_bib46","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"key":"10.7861\/clinmedicine.19-2-169_bib47","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ana.24557","article-title":"What is the optimal sequence of rescue treatments for attacks of neuromyelitis optica spectrum disorder?","volume":"79","author":"Weinshenker","year":"2016","journal-title":"Ann Neurol"},{"key":"10.7861\/clinmedicine.19-2-169_bib48","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"10.7861\/clinmedicine.19-2-169_bib49","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.7861\/clinmedicine.19-2-169_bib50","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/practneurol-2012-000237","article-title":"A practical guide to the treatment of neuromyelitis optica","volume":"12","author":"Palace","year":"2012","journal-title":"Pract Neurol"},{"key":"10.7861\/clinmedicine.19-2-169_bib51","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.7861\/clinmedicine.19-2-169_bib52","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-018-8812-0","article-title":"Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation","volume":"265","author":"Tallantyre","year":"2018","journal-title":"J Neurol"},{"key":"10.7861\/clinmedicine.19-2-169_bib53","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2011","journal-title":"Multiple Sclerosis Journal"},{"key":"10.7861\/clinmedicine.19-2-169_bib54","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1212\/WNL.0b013e31826845fe","article-title":"Does natalizumab therapy worsen neuromyelitis optica?","volume":"79","author":"Jacob","year":"2012","journal-title":"Neurology"},{"key":"10.7861\/clinmedicine.19-2-169_bib55","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch Neurol"},{"key":"10.7861\/clinmedicine.19-2-169_bib56","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/WNL.0b013e318229e694","article-title":"Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study","volume":"77","author":"Kanamori","year":"2011","journal-title":"Neurology"},{"key":"10.7861\/clinmedicine.19-2-169_bib57","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1212\/NXI.0000000000000286","article-title":"Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder","volume":"3","author":"Chavarro","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.7861\/clinmedicine.19-2-169_bib58","unstructured":"58 Business Wire,. Alexion announces successful Phase 3 PREVENT study of Soliris\u00ae (Eculizumab) in patients with neuromyelitis optica spectrum disorder (NMOSD). Business Wire. www.businesswire.com\/news\/home\/20180924005 283\/en\/Alexion- Announces-Successful-Phase-3-PREVENT-Study [Accessed 6 November 2018]."},{"key":"10.7861\/clinmedicine.19-2-169_bib59","doi-asserted-by":"crossref","unstructured":"59 Whittam D, Hamid S, Linaker S, et al. Relapse rates and disability in the modern treatment era of neuromyelitis optica: data from a specialised UK centre. Paris: 7th joint ECTRIMS\u2013ACTRIMS meeting, 2017.","DOI":"10.26226\/morressier.59a3eda8d462b8028d8952a4"},{"key":"10.7861\/clinmedicine.19-2-169_bib60","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1007\/s00415-017-8445-8","article-title":"What\u2019s new in neuromyelitis optica? A short review for the clinical neurologist","volume":"264","author":"Whittam","year":"2017","journal-title":"J Neurol"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824012119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824012119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.7861\/clinmedicine.19-2-169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:32:48Z","timestamp":1761460368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211824012119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1470211824012119"],"URL":"https:\/\/doi.org\/10.7861\/clinmedicine.19-2-169","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuromyelitis optica spectrum disorders","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.7861\/clinmedicine.19-2-169","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Royal College of Physicians 2019. All rights reserved.","name":"copyright","label":"Copyright"}]}}